Trial Profile
A clinical trial to investigate the intravenous formulation of brincidofovir for the prevention and treatment of cytomegalovirus (CMV) and BK virus in haematopoietic cell transplants (HCT) and kidney transplant recipients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 14 May 2018
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary)
- Indications Cytomegalovirus infections; Polyomavirus infections
- Focus Adverse reactions; First in man
- 07 May 2018 According to a Chimerix media release, the company is anticipating interim Phase 2 data in the second half of 2018.
- 08 Nov 2017 According to a Chimerix media release, this trail is expected initiate in the in early 2018.
- 08 Aug 2016 According to a Chimerix media release, this trail is expected initiate in the second half of 2016.